Recent advances in the treatment of rheumatoid arthritis

Clinical Cornerstone

Volumn 2, Issue 2, 1999, Pages 38-50

  Strand, Vibeke ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PLASMAPHERESIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; ISOXAZOLES; PLASMAPHERESIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0033253609     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(99)90013-3     Document Type: Article

References (45)

1. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity [editorial]. J Rheumatol. 1986;13:841-845.
2. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994;120:26-34.
3. Scott DL, Symmons DPM, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108-1111.
4. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol. 1984;11: 158-161.
5. Van der Heide A, Jacobs JWG, Bijlsma JWJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996;124:699-707.
6. Fries JF, Williams CA, Morfeld D, et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996; 39:616-622.
7. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309-318.
8. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996;39:713-722.
9. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for RA in seven rheumatology private practices: II: Second line drugs and prednisone. J Rheumatol. 1992;19:1885-1894.
10. Wolfe F. The epidemiology of drug treatment failure in RA. Baillieres Clin Rheumatol. 1995;9: 619-632.
11. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum. 1990;33:1449-1461.
12. Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis. J Rheumatol. In press.
13. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporin and methotrexate in severe RA. N Engl J Med. 1995;333: 137-141.
14. O'Dell J, Haire C, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three. N Engl J Med. 1996;334:1287-1291.
15. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:723-731.
16. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis clinical trials. Arthritis Rheum. 1995;38:725-735.
17. Kremer JM. Review article. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. In press.
18. Strand V, Cohen S, Schiff M, et al, on behalf of the Leflunomide RA Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med. In press.
19. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicentre trial. Lancet. 1999;353:259-266.
20. Strand V, Emery P, Scott DL, et al. Comparison of the EULAR response criteria (DAS28) and the ACR responder index in 3 trials of leflunomide. In: Abstracts of European League and Association of Rheumatology; June 8, 1999; Glasgow, Scotland.
21. Strand V, Tugwell P, Bombardier C, et al. Function and health related quality of life - results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. In press.
22. Sharp JT, Strand V, Leung H, et al, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of RA - results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. In press.
23. Leflunomide (Arava®) [package insert]. Kansas City, Mo: Hoechst Marion Roussel; September 14, 1998.
24. Weinblatt ME, Kremer JM, Coblyn JS, et al. Efficacy, safety and pharmacokinetics of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. In press.
25. Kollias G. Tumor necrosis factor: a specific trigger in arthritis. Res Immunol. 1993;144:342-347.
26. Beutler B, Cerami A. The biology of cachectin/ TNF - a primary mediator of the host response. Annu Rev Immunol. 1989;7:625-655.
27. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-4031.
28. Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 1996;87:847-857.
29. Moreland LW, Margolies GR, Heck LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996;23:1849-1855.
30. Weinblatt MH, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a TNF receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
31. Etanercept (Enbrel™) [package insert]. Seattle, Wash: Immunex Corporation; November 3, 1998.
32. Etanercept (Enbrel™) [package insert]. Seattle Wash: Immunex Corporation; May 12, 1999.
33. Van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
34. Targan SR, Hanauer SB, van Deventer SJH, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
35. Elliot MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
36. Elliot MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-1127.
37. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41: 1552-1563.
38. Lipsky PJ, St. Clair W, Kavanaugh A, et al. Long term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNFα antibody (infliximab) in patients with active disease on methotrexate [abstract]. Arthritis Rheum. 1998;41: S364.
39. Infliximab (Remicade™) [package insert]. Malvern, Pa: Centocor Inc; August 19, 1998.
40. Felson D, Furst D, LaValley M, et al. Results of a randomized double blind trial of the Prosorba column for treatment of severe rheumatoid arthritis [abstract]. Arthritis Rheum. 1998;41:S364.
41. Furst DE, Felson D, Gendreau M. Patients with severe rheumatoid arthritis responding to treatment respond again on retreatment [abstract]. Arthritis Rheum. 1998;41:S316.
42. Prosorba Protein A Immunoadsorption Column [package insert]. San Diego, Calif: Cypress Bioscience, Inc.
43. Strand V. OMERACT II. The biologics perspective. J Rheumatol. 1995;22:1415-1417.
44. Kavanaugh A, Cohen S, Cush J. Inhibitors of tumor necrosis factor in rheumatoid arthritis: will that dog hunt [editorial]? J Rheumatol. 1998;25:2049-2052.
45. Doig C, Kinsella TD. The ethics of anticytokine therapy for rheumatoid arthritis. J Rheumatol. 1998;25:2053-2055.